Lupin to market Eli Lilly's insulin analog product in India

Eglucent is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. Eglucent will be available in the Indian market in both, the cartridge and disposable pen form. 

Lupin is the fifth largest company in the anti-diabetes segment with a market share of 6.34 percent growing at 18 percent, according to IMS MAT September 2016. The company also has the distinction of being the only company in the Anti-Diabetes market with a contemporary portfolio comprising of oral anti-diabetes drugs (OAD) and injectable drugs like conventional and analog insulins. Lupin’s anti-diabetic portfolio contributes 16 percent to its India formulations sales (FY 2016).

The Indian diabetes market is valued at Rs 9,272 crore and is growing at 19 percent, according to IMS MAT September 2016. The total insulin market is valued at Rs 2,207 crore, out of which the insulin analogue market size is valued at Rs 1,106 crore with a 3 year CAGR of 28 percent. The total insulin Lispro molecule market size is Rs 142 crore with a 3 year CAGR of 24 percent, as per the IMS MAT September 2016.

Shakti Chakraborty, group president, India Region Formulations, Lupin, added, “We are excited about expanding our partnership with Eli Lilly with the launch of Eglucent and the progress that we together have made to combat the rising incidence of diabetes in India. Our entry into the rapid-acting insulin analog segment will not only bolster our existing diabetes portfolio but will also go a long way in strengthening our position in the Indian pharmaceutical market.”